Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acolbifene vs Low Dose Tamoxifen in High Risk Pre-menopausal Women
NCT05941520Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2024
- Primary completion
- Aug 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of acolbifene in breast cancer (2 arms), sponsored by National Cancer Institute. Primary endpoint: Change in expression of the endocrine resistance gene anterior gradient 2 (AGR2) at 6 months. Started Oct 2024; status: recruiting.
02
Drugs
acolbifene
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05941520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05941520.